On January 10, 2025, China’s State Administration for Market Regulation (“SAMR”) put into effect its Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (“Compliance Guidelines”)....more
2/12/2025
/ Anti-Corruption ,
China ,
Clinical Laboratories ,
Compliance ,
Corporate Governance ,
Corruption ,
Enforcement Actions ,
Fraud ,
Health Care Providers ,
Healthcare ,
Healthcare Fraud ,
Medical Research ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Requirements ,
Risk Management
On October 11, 2024, China’s State Administration for Market Regulation (“SAMR”) issued the Draft Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (“Draft Guidelines”). These guidelines...more